GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men
Why the study?
Does plasma GDF-15 level predict long-term risk for cardiovascular disease and cancer morbidity and mortality in elderly men?
Population
940 men from the Uppsala Longitudinal Study of Adult Men (ULSAM) cohort, age 71 at baseline.
Design
Cohort
Follow-up
10 years
Authors
Discussion
Loading...
Member takes
Implication
May refine mortality risk stratification in elderly men; leaves open prospective validation before clinical adoption.
Key Points
- Evaluate GDF-15 as an independent prognostic marker for the long-term risk of cardiovascular disease and cancer morbidity in elderly men.
- Analyzed plasma samples from 940 men in the Uppsala Longitudinal Study of Adult Men at age 71.
- Linked data on mortality and morbidity to public registries over a 10-year follow-up period.
- Assessed associations of GDF-15 with clinical risk factors and major adverse events.
- A 1 SD increase in log GDF-15 correlated with a 48% increase in cardiovascular mortality (95%CI 26-73%, p<0.001) in the total cohort.
- For cancer mortality, GDF-15 correlated with a 46% increase in the total cohort (95%CI 21-77%, p<0.001).
- GDF-15 improved prognostication of cardiovascular and cancer mortality beyond established risk factors and biomarkers.
Structured PICO
Does plasma GDF-15 level predict long-term risk for cardiovascular disease and cancer morbidity and mortality in elderly men?
P
Population
940 men from the Uppsala Longitudinal Study of Adult Men (ULSAM) cohort, age 71 at baseline.
I
Intervention
Plasma GDF-15 levels
O
Outcome
Cardiovascular mortality, total mortality, coronary heart disease morbidity and mortality, and cancer mortality and morbidity at 10 years follow-uphard clinical
In elderly men, elevated GDF-15 levels independently predict long-term cardiovascular and cancer mortality and morbidity beyond established risk factors.
Cite This Study
Wallentin et al. (2013) studied this question.